SGP was first to discover IL-28B polymorphisms highly correlate with SVR. ZGEN owns patents of IL-28A, IL-28B, and IL-29 for the treatment of HCV though.
IL-28B variants have been found to be correlated to patient response to HCV drugs. Most, if not all, new efficacy trials of HCV drugs will likely have to stratify trial arms according to IL-28B variants.
LabCorp licensed IP from MRK in order to commercialize the IL-28B test (#msg-52716245).
Market Data 
Markets 
AI
